MIAMI VALVES 2019
January 31 - February 2, 2019

REGISTER NOW

IMI_logo.png

Save

Save

Save

Save

ADVANCEMENTS IN TRANSCATHETER THERAPIES FOR VALVULAR AND STRUCTURAL HEART DISEASE.

ACCREDITATION

 

Faculty disclosures 

Learning Objectives

Upon completion of this activity, the learner should be able to:

 

 

  • Appraise new and upcoming technologies in the management of structural heart disease, including, valvular heart disease, stroke prevention, hemodynamic support, cardiomyopathy and high risk-percutaneous coronary intervention to determine their benefit for patients
  • Evaluate the relative advantages and disadvantages of different strategies in complex cases involving valvular disease
  • Present indications, techniques, outcomes, and complications for transcatheter valve intervention in patients with native valve lesions
  • Compare FDA approved technologies for TAVR and the scientific data supporting their use
  • Examine best practice techniques for high certainty valve implantation
  • Analyze data and techniques for treatment of bioprosthetic valve dysfunction
  • Evaluate the rationale, challenges, and necessity of the heart team approach to valvular heart disease, and the functionality of the team within a center of excellence
  • Evoke the changing landscape of percutaneous and surgical techniques of valve repair and replacement
  • Evaluate the barriers to care in patients with valvular heart disease with specific attention to current gaps in the timely delivery of percutaneous and surgical interventions
  • Recognize the different diagnostic tools and combinations required to accurately diagnose specific structural heart diseases and plan transcatheter therapy
  • Discuss the rationale and technique of alternative access approach for aortic stenosis
  • Discuss investigational valves in the near horizon including their therapeutic advantages and limitations
  • Describe the advantages and pitfalls of comprehensive diagnostic techniques for patients with valvular heart disease such as cardiac computed tomography, three-dimensional echocardiography, and complex invasive hemodynamic catheterization
  • Discuss transcatheter treatment options for mitral valve disease
  • Explain the clinical data supporting mitral valve leaflet clip approximation for the treatment of mitral regurgitation
  • Demonstrate and present best practice techniques for mitral valve clip approximation
  • Examine alternative investigational devices for the transcatheter treatment of mitral regurgitation
  • Present alternatives with transcatheter aortic and pulmonic valve technologies for the treatment of mitral disease
  • Present progress in transcatheter mitral valve replacement
  • Present the techniques and efficacy of transcatheter treatment of mitral prosthetic valve paravalvular leaks
  • Demonstrate how septal ablation and technologies can improve mitral regurgitation in hypertrophic cardiology.
  • Discuss transcatheter treatment options for tricuspid valve disease
  • Examine the evidence regarding closure of percutaneous closure of patent foramen ovale for stroke prevention.
  • Examine the evidence regarding left atrial appendage exclusion for stroke prevention in patients with atrial fibrillation.
  • Examinethedataandtechniquesforidentificationandassessmentofhemodynamically significant coronary artery lesions.
  • Examine the data and techniques for coronary imaging and lesion characterization.
  • Examine the data and techniques regarding new stent and bio-absorbable scaffolds for percutaneous coronary intervention, as well as devices for coronary intervention facilitation (plaque modification, chronic total occlusion).
  • Examine the data and techniques for the treatment of in-stent restenosis, with emphasizes in new technology.
  • Discuss therapeutic alternatives in patients with atrial fibrillation and the data to support it.
  • Identify the indication, techniques, and complications for left atrial appendage occlusion in patients with Afib.
  • Recognize the risks and benefits of anticoagulation in patients with atrial fibrillation and
  • other co-morbidities.
  • Identify the role for catheter ablation for patients with atrial fibrillation based on the most recent trial
  • Recognize the pathophysiology of atrial fibrillation and potential for new therapeutic targets.
  • Learn and evaluate patients for advanced heart failure therapies.
  • Focused learning related to multi-organ transplant and special heart transplant patient population.
  • Evaluation and basic management of patient with mechanical circulatory support devices including LVADs and Total artificial heart.
  • Case based scenarios discussing complex advanced heart failure patients.

 

 

Target Audience

This activity has been designed to meet the educational needs of invasive cardiologists, interventional cardiologists, vascular surgeons and interventional radiologists.

 

CME Accreditation STATEMENT

Complete Conference Management is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

 

Credit Designation STATEMENT

Complete Conference Management designates this live activity for a maximum of 21.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Other Credits

For the purpose of recertification, American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 CreditTM from organizations accredited by the ACCME.

 

American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 CreditTM from organizations accredited by the ACCME.

 

American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 CreditTM from organizations accredited by the ACCME.

 

UEMS/EACCME CME Credit Recognition

The American Medical Association (AMA) has an agreement of mutual recognition of CME credit with the UEMS. Under the terms of this agreement the European Accreditation Council for Continuing Medical Education (EACCME), the accrediting arm of the UEMS, will convert CME credit for live activities certified by the AMA.

 

Disclaimer

Complete Conference Management makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

 

Disclosure Policy Statement

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Complete Conference Management must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, and planning committee members participating in a CCM-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

 

Disclosure of Unlabeled Use

Complete Conference Management requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.